These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1451 related articles for article (PubMed ID: 18022071)

  • 1. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
    Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; McLaughlin V; Gulati M; Rich S
    Am J Cardiol; 2005 Nov; 96(9):1334-6. PubMed ID: 16253609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China].
    Xiong CM; He JG; Lu XL; Shan GL; Wu BX; Zhu XY; Wu GH; Zeng XF; Guo T; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Tian HY; Li WM; Zhang DZ; Zhang C; Li MT; Liu HM; Guo YJ; Shen JY; Zhang WJ; Liu S; Zhou DX; Bao CD; Huang SA; Chen JY; Wu WF; Huang K; Li CL; Wang LH; He B
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):370-4. PubMed ID: 21418907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
    Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
    J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease.
    Lu XL; Xiong CM; Shan GL; Zhu XY; Wu BX; Wu GH; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zhang DZ; Li WM; Zhang C; Tian HY; Guo YJ; Guo T; Liu HM; Zhang WJ; Gu H; Huang SA; Chen JY; Wu WF; Huang K; Li JJ; He JG
    Cardiovasc Ther; 2010 Dec; 28(6):350-5. PubMed ID: 20637015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
    Ruiz MJ; Escribano P; Delgado JF; Jiménez C; Tello R; Gómez MA; de la Calzada CS
    J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
    Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
    Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sildenafil therapy for pulmonary hypertension: a prospective study].
    Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zeng WJ; Zhu F; He JG
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):419-23. PubMed ID: 21781512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.
    Xu XQ; Jing ZC; Zhang JH; Wu Y; Wang Y; Jiang X; Wang ZX; Sun YG; Pu JL; Yang YJ
    Hypertens Res; 2009 Oct; 32(10):911-5. PubMed ID: 19644505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.